Challenges to Women’s Adoption of the Human Papillomavirus Vaccine in India: An Updated Review

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 2 | 02 | Page :
    By

    Brij bhushan Sharma,

  1. Student, Himachal pharmacy college, Himachal Pradesh, India

Abstract

The widespread availability of human papillomavirus (HPV) vaccines in some countries throughout the last ten years has demonstrated encouraging outcomes in reducing HPV infection and associated conditions including warts and precancerous lesions. We highlight vaccination coverage and efficacy in this study, which includes the most recent data on available HPV vaccinations. Furthermore, the topic of pan-gender immunisation and ongoing clinical trials is covered. Increasing vaccination coverage is now something that needs more work, particularly in low- and middle-income nations. One of the most important steps we can take is to raise awareness and educate people about HPV and the benefits of getting vaccinated. The next step in vaccine development is to create vaccinations that target HPV strains that are not covered by the ones that are currently available. Future research should monitor and assess all HPV-related cancers, including anal and head and neck cancers, particularly in nations that have implemented pan-gender immunisation initiatives. Further research on therapeutic vaccinations should be conducted in conjunction with other cancer treatments. HPV vaccine was introduced in India in 2008, when bivalent and quadrivalent vaccines were licensed. A nonavalent vaccine was licensed in 2018. The Serum Institute of India launched its first indigenous HPV vaccine, Cervavac, in January 2023.

Keywords: human papillomavirus, vaccine, Cervarix, Gardasil, Gardasil 9, Cervavac.

How to cite this article:
Brij bhushan Sharma. Challenges to Women’s Adoption of the Human Papillomavirus Vaccine in India: An Updated Review. International Journal of Vaccines. 2025; 02(02):-.
How to cite this URL:
Brij bhushan Sharma. Challenges to Women’s Adoption of the Human Papillomavirus Vaccine in India: An Updated Review. International Journal of Vaccines. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijv/article=2025/view=234898


References

  1. Fowler, R., Maani, E. V., Dunton, C. J., Gasalberti, D. P., & Jack, B. W. (2017). Cervical cancer.
  2. Cervical Cancer Screening Every 5 Years Cancer Discov. 2018 Oct;8(10):1204.
  3. Farghaly H, Bourgeois D, Houser PM, Padmanabhan V, Lage JM, Hoda RS. Routine vaginal Pap test is not useful in women status-post hysterectomy for benign Diagn Cytopathol. 2006 Sep;34(9):640-3.
  4. Foran C, Brennan Prevention and early detection of cervical cancer in the UK. 2015 May 28-Jun 10Br J Nurs. 24(10):S22-4, S26, S28-9.
  5. Pierre-Victor D, Stephens DP, Omondi A, Clarke R, Jean-Baptiste N, Madhivanan Barriers to HPV Vaccination Among Unvaccinated, Haitian American College Women. Health Equity. 2018;2(1):90-97.
  6. Manini I, Montomoli Epidemiology and prevention of Human Papillomavirus. Ann Ig. 2018 Jul-Aug;30(4 Supple 1):28-32.
  7. Ghosh I, Mandal R, Kundu P, Biswas J. Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical J Clin Diagn Res. 2016 Feb;10(2):XE01-XE06.
  8. Wang X, Huang X, Zhang Involvement of Human Papillomaviruses in Cervical Cancer. Front Microbiol. 2018;9:2896.
  9. Romero-Masters JC, Lambert PF, Munger Molecular Mechanisms of MmuPV1 E6 and E7 and Implications for Human Disease. Viruses. 2022 Sep 28;14(10)
  10. Choi PW, Liu TL, Wong CW, Liu SK, Lum YL, Ming WK. The Dysregulation of MicroRNAs in the Development of Cervical Pre-Cancer-An Int J Mol Sci. 2022 Jun 27;23(13)
  11. Zhang S, Xu H, Zhang L, Qiao Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020 Dec 31;32(6):720-728.
  12. Hutchcraft ML, Miller Bleeding from Gynecologic Malignancies. Obstet Gynecol Clin North Am. 2022 Sep;49(3):607-622.
  13. Zhdan VM, Holovanova IA, Vovk OY, Korosh MV. RELATIONSHIP BETWEEN CERVICAL CANCER AND THE LEVEL OF PREVENTIVE ONCOLOGICAL EXAMINATIONS. Wiad Lek. 2021;74(6):1428-1432.

 

  1. Fowler, J. R., Maani, E. V., Dunton, C. J., Gasalberti, D. P., Jack, B. W., & Miller, J. L. (2023). Cervical Cancer (Nursing). In StatPearls [Internet]. StatPearls Publishing.
  2. Rauh-Hain JA, Melamed A, Schaps D, Bregar AJ, Spencer R, Schorge JO, Rice LW, Del Carmen Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies. Gynecol Oncol. 2018 Apr;149(1):4-11.
  3. Wang X, Huang X, Zhang Y. Involvement of Human Papillomaviruses in Cervical Front Microbiol. 2018;9:2896
  4. Spinner C, Ding L, Bernstein DI, Brown DR, Franco EL, Covert C, Kahn JA. Human Papillomavirus Vaccine  Effectiveness  and  Herd  Protection  in  Young Pediatrics. 2019 Feb;143(2)
  5. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68: 698– 702.
  6. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016; 65: 1405– 8.
  7. World Health Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions . Geneva: WHO; 2014.
  8. Schiller JT, Castellsague X, Garland A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30( suppl 5): F123– 38.
  9. Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Queen B, et al. Youth Risk Behavior Surveillance—United States, 2017. MMWR Surveill Summ . 2018; 67: 1–
  10. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325– 39.
  11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. HPV PATRICIA Study Group [published erratum appears in Lancet 2010;376:1054]. Lancet 2009; 374: 301– 14.
  12. John F Modlin, Ananda S Bandyopadhyay, Roland Sutter, Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication, The Journal of Infectious Diseases, Volume 224, Issue Supplement_4, 1 October 2021, Pages S398– S404, https://doi.org/10.1093/infdis/jiaa622
  13. T. Schiller, X. Castellsagué, S.M. Garland A review of clinical trials of human papillomavirus prophylactic vaccinesVaccine, 30 (2012), pp. F123-F138

 

  1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
  2. Kaarthigeyan, (2012). Cervical cancer in India and HPV vaccination. Indian Journal of Medical and Paediatric Oncology, 33(01), 7-12
  3. Prinja S, Bahuguna P, Faujdar DS, et al. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: implications for India’s universal immunization program. Cancer 2017; 123: 3253–60.
  4. Technical Advisory Group on Minutes of the meeting of the National Technical Advisory Group on Immunization (NTAGI). Tuesday, December 19, 2017. Nirman Bhawan, New Delhi. Ministry of Health and Family Welfare. Dec 19, 2017. https://mohfw.gov.in/sites/default/files/ Approved%20Minutes%20of

%20NTAGI%20meeting%20held%20 on%20December%2019%202017.pdf (accessed Feb 11, 2019).

  1. Mehrotra R, Hariprasad R, Rajaraman P, et Stemming the wave of cervical cancer: human papillomavirus vaccine introduction in India. J Glob Oncol 2018; 4: 1–4
  2. Sankaranarayanan, , Basu, P., Kaur, P., Bhaskar, R., Singh, G. B., Denzongpa, P., … & Purushotham, A. (2019). Current status of human papillomavirus vaccination in India’s cervical cancer prevention efforts. The Lancet Oncology, 20(11), e637-e644.
  3. Gupta, , Kumar, P., & Das, B. C. (2023). Challenges and opportunities to making Indian women cervical cancer free. Indian Journal of Medical Research, 158(5&6), 470-475.
Ahead of Print Subscription Review Article
Volume 02
02
Received 01/05/2025
Accepted 22/05/2025
Published 27/12/2025
Publication Time 240 Days
62

Login


My IP

PlumX Metrics